

- Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. *Neuro Oncol* 2012;14:v1–v49.
- Villano JL, Koshy M, Shaikh H, et al. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. *Br J Cancer* 2011;105:1414–1418.
- Swerdlow SH, Campo E, Harris NL, et al., eds. *WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues*. Lyon, France: International Agency for Research on Cancer; 2008.
- Ponzoni M, Issa S, Batchelor TT, et al. Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma. *Ann Oncol* 2014;25:316–322.
- Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. *J Clin Oncol* 2005;23:5034–5043.
- Chan CC, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. *Oncologist* 2011;16:1589–1599.
- Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. *J Clin Oncol* 2003;21:266–272.
- Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. *J Clin Oncol* 2006;24:5711–5715.
- Mathew BS, Carson KA, Grossman SA. Initial response to glucocorticoids: a potentially important prognostic factor in patients with primary CNS lymphoma. *Cancer* 2006;15:383–387.
- Bellinzona M, Roser F, Ostertag H, et al. Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. *Eur J Surg Oncol* 2005;31:100–105.
- Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. *Int J Radiat Oncol Biol Phys* 1992;23:9–17.
- Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? *J Clin Oncol* 1998;16:1561–1567.
- DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. *J Clin Oncol* 2002;20:4643–4648.
- Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. *Lancet* 2009;374:1512–1520.
- Correa DD, Maron L, Harder H, et al. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. *Ann Oncol* 2007;18:1145–1151.
- Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. *J Clin Oncol* 2013;31:3971–3979.
- Doolittle ND, Korfel A, Lubow MA, et al. Long-term cognitive function, neuroimaging and quality of life in primary CNS lymphoma. *Neurology* 2013;81:84–92.
- Juergens A, Pels H, Rogowski S, et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. *Ann Neurol* 2010;67:182–189.
- Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. *Lancet Oncol* 2010;11:1036–1047.
- Ferreri AJ, Guerra E, Regazzi M, et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. *Br J Cancer* 2004;90:353–358.
- Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. *J Clin Oncol* 2003;21:1044–1049.
- Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). *J Clin Oncol* 2013;31:3061–3068.
- Khan RB, Shi W, Thaler HT, et al. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? *J Neurooncol* 2002;58:175–178.
- Sierra Del Rio M, Ricard D, Houillier C, et al. Prophylactic intrathecal chemotherapy in primary CNS lymphoma. *J Neurooncol* 2012;106:143–146.
- Batchelor TT, Grossman SA, Mikkelsen T, et al. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. *Neurology* 2011;76:929–930.
- Illerhaus G, Fritsch K, Egerer G, et al. Sequential high dose immunotherapy followed by autologous peripheral blood stem cell transplantation for patients with untreated primary central nervous system lymphoma—a multicentre study by the Collaborative PCNSL Study Group Freiburg. Presented at: 2012 American Society of Hematology Annual Meeting; 2012; Atlanta, GA.
- Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States 2006-2010. *Neuro-Oncol* 2013;14:iii–ii56.
- Nayak L, Batchelor TT. Recent advances in treatment of primary central nervous system lymphoma. *Curr Treat Options Oncol* 2013;14:539–552.
- Jahnke K, Korfel A, Martus P, et al. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. *Ann Oncol* 2005;16:445–449.
- Zhu JJ, Gerstner ER, Engler DA, et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. *Neuro Oncol* 2009;11:211–215.
- Omuro A, Chinot O, Taillandier L, et al. Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine, vincristine, and cytarabine for primary CNS lymphoma (PCNSL) in the elderly: an Ancof and Goelams Intergroup study. Presented at: 2013 American Society of Clinical Oncology Annual Meeting; 2013; Chicago, IL.
- Plotkin SR, Betensky RA, Hochberg FH, et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. *Clin Cancer Res* 2004;10:5643–5646.
- Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. *J Clin Oncol* 2008;26:2512–2518.
- Kasenda B, Schorb E, Fritsch K, et al. Primary CNS lymphoma—radiation-free salvage therapy by second autologous stem cell transplantation. *Biol Blood Marrow Transplant* 2011;17:281–283.
- Nguyen PL, Chakravarti A, Finkelstein DM, et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. *J Clin Oncol* 2005;23:1507–1513.
- Hottinger AF, DeAngelis LM, Yahalom J, et al. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. *Neurology* 2007;69:1178–1182.
- Lai R, Abrey LE, Rosenblum MK, et al. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. *Neurology* 2004;62:451–456.
- Monje ML, Vogel H, Masek M, et al. Impaired hippocampal neurogenesis after treatment for central nervous system malignancies. *Ann Neurol* 2007;62:515–520.
- Mead GM, Bleehen NM, Bullimore GA, et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. *Cancer* 2000;89:1359–1370.